Introduction
============

Pseudomyxoma peritonei (PMP) is a rare gastrointestinal malignancy^[@bib1]^ that is characterized by low-grade mucin-producing metastatic implants on peritoneal surfaces. Although patients with PMP may have an indolent course, they frequently experience recurrent accumulations of gelatinous mucin. The natural history and biology of PMP are distinctive from colorectal carcinoma, and PMP is predominantly locoregionally aggressive. The primary treatment for PMP is surgical debulking,^[@bib2]^ and when there is a recurrence, further cytoreductive surgery and hyperthermic intraperitoneal (IP) chemotherapy can be considered.^[@bib3]^ One center reported a median survival of 6.72 years in patients treated with aggressive cytoreductive surgery and hyperthermic IP chemoperfusion.^[@bib4]^ Our center uses IP chromic phosphate P32 and fluorouracil after maximal surgical resection,^[@bib5]^ and the overall survival with this approach was 8.1 years. Patients who had optimal surgical cytoreduction received postoperative IP chemotherapy and experienced a median survival of 23.5 years, whereas patients who did not achieve optimal surgical cytoreduction and who did not receive postoperative IP chemotherapy had a median survival of 7.5 years.^[@bib5]^

Because PMP is encountered infrequently, few studies have been done on the molecular alterations of this malignancy. Many of the studies to date have focused on mutations commonly seen in colorectal cancer, particularly *KRAS* and its prognostic importance.^[@bib6],\ [@bib7],\ [@bib8]^ In this study, samples from 10 patients with PMP were tested for the presence of a genetic mutation by next-generation sequencing technology. The genomic changes were comprehensively profiled on an individual basis. We hypothesized that next-generation exomic sequence analysis would lead to the discovery of recurrent and common mutational markers in PMP, which may lead to the identification of potential molecular targets for personalized oncological therapy.

Materials and methods
=====================

Patient selection and treatment
-------------------------------

The study was approved by the Mayo Clinic Institutional Review Board. Ten patients with a diagnosis of PMP were selected on the basis of availability of formalin-fixed paraffin-embedded (FFPE) archival slides, adequacy of clinical notes and duration of follow-up. These patients were treated at Mayo Clinic, Rochester, MN, USA between September 2002 and August 2004. A retrospective medical record review of these 10 patients was completed in March 2013. All patients underwent surgical resection, with or without postoperative chemotherapy. The surgical intent was definitive for all patients, and operative reports were reviewed. Intraoperatively, all patients had bulky and peritoneally disseminated disease, and all of their submitted surgical specimens were stored and available for analysis. Patients whose disease was debulked to a residual disease no greater than 3 mm were considered optimally debulked and received IP chemotherapy postoperatively. The postoperative regimen has been described previously in detail,^[@bib5]^ namely, IP fluorouracil and chromic phosphate P32, a β-emitting colloid with an activity of 10 mCi. Fluorouracil was given daily for 3 consecutive days, followed by IP phosphate P32, which was given the day after the IP fluorouracil infusions were complete.

Mutational analyses and detection
---------------------------------

Original hematoxylin and eosin slides were reviewed for the presence of invasive cystadenocarcinoma or adenocarcinoma cells by one of us, a surgical pathologist (RPG) to confirm the pathological diagnosis of PMP. The presence of an invasive component by PMP was confirmed in all 10 cases, which were used in the genome-wide analysis. The clinicopathological Ronnett\'s criteria^[@bib9]^ were applied retrospectively. The sections with the highest ratio of tumor to nonmalignant tissues were selected. No control was used in this study. Archival FFPE slides were then obtained and cut into 10 separate 5-μm sections. Mutations in DNA in 236 cancer-related genes, which included at least 3230 exons and 47 introns from 19 genes often rearranged or altered in somatic human cancer, were then tested using the Illumina HiSeq2000 platform (Foundation Medicine, Cambridge, MA, USA) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Next-generation sequencing technology is capable of genotyping individual base pairs by detecting multiple copies of exonal mutations and fusion genes. For our assay, the power of average coverage for uniquely mapping reads is \> × 900.^[@bib10]^ Sequence data are used for a proprietary data analysis by Foundation Medicine, as described elsewhere,^[@bib11]^ that includes mapping to a reference human genome and comparing genomic DNA sequence coverage with a process-matched normal control sample. Additionally, we performed a *post hoc* immunohistochemical analysis (Histoserv, Inc., Germantown, MD, USA), using *MCL1* (myeloid cell leukemia sequence 1) primary antibody staining on FFPE slides that were sectioned into 3-μm slides and stained with *MCL1* monoclonal antibody (ab31948; Abcam, Cambridge, MA, USA).

Statistical methods
-------------------

Descriptive statistics were used to summarize patient, tumor and mutational characteristics and were reported as median and range or number and frequency. The *χ*^2^ testing (new reference) was performed for trend estimates and correlation of mutational status in patient samples.^[@bib12]^ The *χ*^2^ analysis examined the distribution of attributes between the two sets of observations and performed a goodness-of-fit evaluation of the samples. *P* value of ⩽0.05 was considered statistically significant. Survival since diagnosis was calculated according to the log-rank Kaplan--Meier method.^[@bib13]^ All tests were two sided, with 5% type I error rates.

Results
=======

Clinical and tumor characteristics
----------------------------------

Selected patient and tumor characteristics are shown in [Table 1](#tbl1){ref-type="table"}. All patients had PMP evident at the time of surgery as low-grade mucinous neoplasms of the appendix with abundant intra-abdominal mucin and scant neoplastic cells. Eight of the 10 cases were low grade, with 2 cases (patients 1 and 10) with moderate cytological atypia noted as grade 3 (of 4 maximum) at our institution. None of these cases was high grade (that is, severe atypia, grade 4 of 4). The median follow-up was 5.5 years (range, 2.0--9.3 years) for all 10 patients, and 8.0 years (range, 4.3--9.3 years) in 4 patients who remained alive at the time of this analysis. The most common presentation was abdominal pain, which occurred in seven patients, with a median duration of 21 days (range, 0--135 days) between the onset of symptoms and evaluation by a medical provider. Additionally, patients also experienced weight loss (in four) and fatigue (in three) but rarely fever (in one) or bowel obstruction (none). On physical examination, ascites was a common finding, occurring in seven patients but rarely found were a palpable mass (in one) or peritoneal signs (in two). All patients underwent exploratory laparotomy during which the analyzed tissue samples were obtained, and 9 of the 10 patients had \>1 organ resected in addition to the peritoneum, appendix and colon (most commonly, omentum (8 of the 9 patients); 3 had splenectomy as well). Six patients received IP fluorouracil for 3 days followed by IP phosphorus P32.

*MCL1* and *JUN* amplifications
-------------------------------

Eight of the 10 samples had ⩾1 detectable mutation ([Table 2](#tbl2){ref-type="table"}). The median number of genetic alterations was 2 (range, 0--4). Two samples had no identifiable mutations. *MCL1* and *JUN* were concurrently amplified in three samples, of which two had concurrent *KRAS* codon 12 and *GNAS* codon 201 substitutions. One sample with *MCL1* and *JUN* amplification had concurrent amplification of *MYC* and *NFKBIA*.

Additional slides were prepared for immunohistochemical staining for cytoplasmic expression of *MCL1* ([Figure 1](#fig1){ref-type="fig"}). Three samples had moderate-to-strong staining, five had moderate staining and two had weak staining. *MCL1* expression was detected in samples with *MCL1* amplification; however, *MCL1* expression was also detected in other samples that did not have *MCL1* amplification.

*KRAS*, *GNAS* and other mutations
----------------------------------

The specific *KRAS* and *GNAS* mutations for each patient are summarized in [Table 3](#tbl3){ref-type="table"}. *KRAS* mutations were detected in seven patients. Six of the seven *KRAS* mutations involved codon 12, and one involved codon 59. Aspartic acid replaced glycine in four of these mutations (G12D). Valine (G12V) and alanine (G12A) each replaced glycine in the other two codon 12 mutations. We also detected a single *KRAS* A59T mutation. We detected four *GNAS* mutations, which manifested as two R201H and two R201C substitutions each. All four of these samples also had concurrent *KRAS* codon 12 substitutions. *ZNF703* was amplified in one sample with a *KRAS* G12A substitution, without an associated *GNAS* mutation. Comutations in both codons 12 and 59 of *KRAS* were not found.

Survival
--------

At the time of analysis, 6 patients (60%) had died. The median overall survival for this group of 10 patients was 5.3 years ([Figure 2](#fig2){ref-type="fig"}). Of the 10 patients, 9 experienced recurrence, including 7 locoregionally and 2 with persistent disease. Five patients underwent repeat attempts at cytoreduction for symptomatic disease recurrence (two with additional organs removed). Salvage chemotherapy regimens included two cycles of irinotecan, fluorouracil and leucovorin, then two cycles of irinotecan and cetuximab (in one patient) and leucovorin, fluorouracil and oxaliplatin (in two patients).

The coamplification of *MCL1* or *JUN* demonstrated a slight trend favoring prolonged survival (median not reached vs 4.8 years, *χ*^2^=2.93, Wilcoxon *P*=0.09). Four patients were alive at the time of analysis; all three patients with both *MCL1* and *JUN* amplified were still alive at 7.3, 4.3 and 8.7 years (patients 3, 8 and 9, respectively). Patient 3 was the only patient living without evidence of disease. Patient 6, alive and with the longest follow-up of 9.3 years, did not have *MCL1* and *JUN* coamplification.

Discussion
==========

We found mutations in 80% of our patients with PMP. We are the first, to our knowledge, to report coamplification of *MCL1* and *JUN* in PMP, and we confirm previous findings of *KRAS* and *GNAS* mutations in PMP.

*MCL1* is a *BCL2*-related anti-apoptotic gene important for myeloid differentiation.^[@bib14]^ It has been mapped to the long arm of the first chromosome (1q21), an area that is rearranged in many malignancies.^[@bib15]^ *MCL1* is upregulated in chronic lymphocytic leukemia,^[@bib16]^ hepatocellular carcinoma,^[@bib17]^ breast cancer^[@bib18]^ and non-small cell lung cancer.^[@bib19]^ Overexpression of *MCL1* in breast cancer was correlated with higher grade and poor survival.^[@bib18]^ In at least one patient in the current study, amplification of *MCL1* was associated with amplification of *MYC*. Coexpression of *MCL1* and *MYC* is associated with poor survival in non-small cell lung cancer.^[@bib20]^ *MCL1* can potentially be targeted.^[@bib21]^ *MCL1* overexpression appears to have a key role in the resistance of some cancers to chemotherapy, particularly fluorouracil, which is often given IP for PMP. Because of *MCL1*\'s short half-life, inhibiting its expression or neutralizing its function can induce rapid apoptosis in several cancer cell lines.^[@bib22]^

*JUN* is a proto-oncogene similar to the transforming gene of avian sarcoma virus 17.^[@bib23]^ This gene has no introns and is mapped to the short arm of chromosome 1 at 1p32-p31.^[@bib24],\ [@bib25]^ *JUN* is commonly expressed in gastroenteropancreatic neuroendocrine tumors,^[@bib26]^ and its expression is correlated with worse survival in squamous cell lung cancers.^[@bib27]^

*KRAS* mutations have been reported in mucinous appendiceal adenocarcinomas. One recent study identified *KRAS* mutations in 37 of 64 patients (57.8%).^[@bib28]^ Of the 35 patients with specific mutation data, 31 had a codon 12 mutation, and the other 4 had a codon 13 mutation. There was no difference in the distribution of *KRAS* mutations between low-grade and high-grade PMPs, nor was there a difference in survival between those with or without a *KRAS* mutation. Similarly, another earlier study identified *KRAS* mutations in 8 of 16 samples (50%).^[@bib29]^ The most common mutation was *KRAS* G12A, but G12T and G13A substitutions were also identified. More recently, a slightly higher rate of 61.3% of *KRAS* mutations in PMP of the appendix was reported.^[@bib4]^ Previous studies have also reported a substantial incidence of *KRAS* mutations in their PMP patients, which are similar to our findings.^[@bib30],\ [@bib31]^ Although *KRAS* was not prognostic in our study or in previous studies of PMP, it has been associated with poor prognosis in colorectal cancer.^[@bib32],\ [@bib33],\ [@bib34]^

*GNAS* R201H is an activating mutation of the α-subunit of a G-protein that is coupled to seven transmembrane receptors, leading to constitutive activation of adenylyl cyclase.^[@bib35],\ [@bib36]^ More recent work identified *GNAS* R201H substitution in half the low-grade appendiceal mucinous neoplasms that they studied but not in any mucinous adenocarcinomas.^[@bib37]^ When *GNAS* R201H was introduced into a colorectal cancer cell line, increases in cyclic AMP and mucin production but not proliferation were observed.

A number of interesting findings appeared in the samples that underwent next-generation sequencing for PMP. The *MCL1* and *JUN* mutations were novel for these patients, and they amplified concurrently in three patients. No additional single mutation for any individual tumor case was detected. Additionally, all three patients were long-term survivors. We hypothesize that the coamplification status of both *MCL1* and *JUN* represents a new favorable prognostic marker in patients with PMP; however, a larger-scale analysis is required to determine this.

We also noticed that 2 of the 10 patients carried no detectable mutations by next-generation sequencing. However, at the time of analysis, patient 6 was alive with disease at 9.3 years of follow-up, while patient 7 died with disease 2.8 years after his diagnosis. It is possible that additional genetic aberrations harbored by their PMP tumors went undetected with the technique we chose for analysis. Certainly, more clinical, socioeconomic and pathological factors than genetic mutational status can influence a patient\'s eventual survival.

Next-generation sequencing is a DNA-based technique, which requires further evaluation to validate its role in routine clinical practice. Amplifications of genes do not always correlate with gene expression, and other mechanisms can influence the level of protein expression. For example, next-generation sequencing may fail to capture epigenetic changes such as promoter methylation or histone acetylation that can also influence gene expression. Post translational events such as translational repression by microRNA are also not captured by next-generation sequencing. Although all cases in which we observed *MCL1* amplification demonstrated some degree of *MCL1* expression, expression of *MCL1* was stronger in a few samples without amplification. The mechanisms of *MCL1* expression in PMP are the subject of ongoing investigations.

Although our study is limited by the small sample size, the purpose of this research was to identify novel mutations that may help us in the treatment of PMP. Our clinical and gene-based results, especially regarding *MCL1* and *JUN* amplification rates, are not epidemiological, as data were not controlled. Although PMP is rare, the patients affected by this disease need improved prognostication and therapies.

Conclusion
==========

We identified coamplification of *MCL1* and *JUN* in PMP. Additionally, we confirmed the numerous *KRAS* and *GNAS* mutations reported previously. *MCL1* and *JUN* may represent novel prognostic markers or targets for treatment of PMP and require further study.

This work is supported by the Seed Grant for translational biology of pseudomyxoma peritonei, National Organization for Rare Disorders, BU70308/FP60037, awarded in June 2010. Portions of this work were presented in abstract form at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA, October 19--23, 2013.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies the paper on Journal of Human Genetics website (http://www.nature.com/jhg)

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

![Immunohistochemical staining for MCL1 in two patient samples demonstrated moderate (left, patient 2) and moderate-to-strong (right, patient 6) cytoplasmic staining. Both patients had unique *MCL1* and *JUN* coamplification in samples of pseudomyxoma peritonei tested by next-generation genetic sequencing (original magnification × 200, left; × 100, right).](jhg2013132f1){#fig1}

![Overall survival of 10 patients with pseudomyxoma peritonei.](jhg2013132f2){#fig2}

###### Demographic, tumor and clinical characteristics in 10 patients with pseudomyxoma peritonei

  *Patient no./sex/age at diagnosis, years*   *Ascites at diagnosis*   *PMP histology*   *Primary site*   *Extent of diagnosis*   *PMP grade (of 4)*   *Extent of surgery*   *Postoperative chemotherapy (phosphorus P32 and fluorouracil)*   *Disease status*
  ------------------------------------------- ------------------------ ----------------- ---------------- ----------------------- -------------------- --------------------- ---------------------------------------------------------------- ------------------
  1/M/76.8                                    Yes                      CA                Appen            Diff                    3                    Max                   Yes                                                              DWD
  2/M/42.2                                    Yes                      A                 Colon            Diff                    2                    P                     No                                                               DWD
  3/F/59.7                                    No                       A                 Appen            Diff                    1                    Max                   Yes                                                              AWOD
  4/M/75.2                                    Yes                      CA                Appen            Diff                    2                    Max                   Yes                                                              DWD
  5/M/53.4                                    Yes                      A                 Appen            Diff                    1                    P                     Yes                                                              DWD
  6/M/48.6                                    No                       A                 Appen            Diff                    1                    Max                   Yes                                                              AWD
  7/M/35.2                                    Yes                      A                 Appen            Diff                    2                    Max                   Yes                                                              DWD
  8/F/82.0                                    Yes                      A                 Appen            LA                      1                    Max                   No                                                               AWD
  9/M/70.2                                    No                       A                 Appen            Diff                    1                    Max                   No                                                               AWD
  10/F/74.0                                   No                       A                 Appen            Diff                    3                    P                     No                                                               DWD

Abbreviations: A, adenocarcinoma; Appen, appendix; AWD, alive with disease; AWOD, alive without disease; CA, cystadenocarcinoma; Diff, diffuse; DWD, dead with disease; LA, localized to appendix; Max, maximally debulked, all gross disease removed; P, partially debulked; PMP, pseudomyxoma peritonei.

###### Summary of somatic genetic mutations and rearrangements detected by next-generation sequencing assay and results of *MCL1* IHC staining

  *Patient no.*   *KRAS mutation*   *GNAS mutation*   *Other mutations*                                    *MCL1 IHC staining*   *No. of genetic alterations*
  --------------- ----------------- ----------------- ---------------------------------------------------- --------------------- ------------------------------
  1               G12D              R201H                                                                  Moderate              2
  2               A59T                                *hMLH1* micro satellite instability                  Moderate              1[a](#t2-fn2){ref-type="fn"}
  3               G12V              R201C             Amplification of *MCL1* and *JUN*                    Weak                  4
  4               G12D                                                                                     Weak                  1
  5               G12A                                Amplification of *ZNF703*                            Moderate              2
  6                                                   None detected                                        Moderate to strong    0
  7                                                   None detected                                        Moderate to strong    0
  8               G12D              R201H             Amplification of *MCL1* and *JUN*                    Moderate              4
  9                                                   Amplification of *MCL1*, *MYC*, *JUN* and *NFKBIA*   Moderate              4
  10              G12D              R201C                                                                  Moderate to strong    2

Abbreviation: IHC, immunohistochemical.

The *hMLH1* microsatellite instability was not counted.

###### Summary of detected *KRAS* and *GNAS* mutations in 8 of 10 patients with pseudomyxoma peritonei

  *Patient no.*   *KRAS A59T*   *KRAS G12A*   *KRAS G12D*   *KRAS G12V*   *GNAS R201C*   *GNAS R201H*   *Any KRAS codon mutation*   *Any GNAS 201 mutation*
  --------------- ------------- ------------- ------------- ------------- -------------- -------------- --------------------------- -------------------------
  1               0             0             1             0             0              1              1                           1
  2               1             0             0             0             0              0              1                           0
  3               0             0             0             1             1              0              1                           1
  4               0             0             1             0             0              0              1                           0
  5               0             1             0             0             0              0              1                           0
  8               0             0             1             0             0              1              1                           1
  9               0             0             0             0             0              0              0                           0
  10              0             0             1             0             1              0              1                           1
  Total           1             1             4             1             2              2              7                           4
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